Compare Stocks: DNLI, BEAM, IBRX, and MDGL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$23.47 -5.1%	$26.30	$20.23 ▼ $38.26	$2.42B	2.2	1.83 million shs	1.65 million shs
DNLI Denali Therapeutics	$17.61 -4.0%	$21.79	$13.75 ▼ $27.30	$2.81B	1.02	2.04 million shs	2.30 million shs
IBRX ImmunityBio	$9.18 -8.2%	$8.57	$1.95 ▼ $12.43	$9.73B	0.02	15.89 million shs	21.48 million shs
MDGL Madrigal Pharmaceuticals	$449.74 -2.2%	$515.06	$393.61 ▼ $615.00	$10.39B	-1.04	283,726 shs	364,533 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	-8.68%	-4.86%	-14.75%	-13.68%
DNLI Denali Therapeutics	0.00%	-9.46%	-12.52%	-24.39%	+7.97%
IBRX ImmunityBio	0.00%	-12.65%	+8.51%	+19.53%	+255.81%
MDGL Madrigal Pharmaceuticals	0.00%	-4.67%	-15.84%	-18.74%	+3.76%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$23.47 -5.1%	$26.30	$20.23 ▼ $38.26	$2.42B	2.2	1.83 million shs	1.65 million shs
DNLI Denali Therapeutics	$17.61 -4.0%	$21.79	$13.75 ▼ $27.30	$2.81B	1.02	2.04 million shs	2.30 million shs
IBRX ImmunityBio	$9.18 -8.2%	$8.57	$1.95 ▼ $12.43	$9.73B	0.02	15.89 million shs	21.48 million shs
MDGL Madrigal Pharmaceuticals	$449.74 -2.2%	$515.06	$393.61 ▼ $615.00	$10.39B	-1.04	283,726 shs	364,533 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	-8.68%	-4.86%	-14.75%	-13.68%
DNLI Denali Therapeutics	0.00%	-9.46%	-12.52%	-24.39%	+7.97%
IBRX ImmunityBio	0.00%	-12.65%	+8.51%	+19.53%	+255.81%
MDGL Madrigal Pharmaceuticals	0.00%	-4.67%	-15.84%	-18.74%	+3.76%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.75	Moderate Buy	$50.10	113.46% Upside
DNLI Denali Therapeutics	2.75	Moderate Buy	$35.85	103.56% Upside
IBRX ImmunityBio	2.71	Moderate Buy	$16.00	74.29% Upside
MDGL Madrigal Pharmaceuticals	2.78	Moderate Buy	$699.20	55.47% Upside

Current Analyst Ratings Breakdown

Latest DNLI, BEAM, IBRX, and MDGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	BEAM Beam Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	DNLI Denali Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	MDGL Madrigal Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$80.00
10/15/2026	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$15.00
10/14/2026	IBRX ImmunityBio	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$12.00 ➝ $14.00
10/14/2026	IBRX ImmunityBio	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$16.00
10/14/2026	MDGL Madrigal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$735.00
10/14/2026	BEAM Beam Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$65.00
10/6/2026	IBRX ImmunityBio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/25/2026	IBRX ImmunityBio	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy

(Data available from 10/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$139.74M	17.35	N/A	N/A	$12.20 per share	1.92
DNLI Denali Therapeutics	$3.60M	781.05	N/A	N/A	$6.91 per share	2.55
IBRX ImmunityBio	$113.29M	85.88	N/A	N/A	($0.51) per share	-18.00
MDGL Madrigal Pharmaceuticals	$1.28B	8.09	N/A	N/A	$26.54 per share	16.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
DNLI Denali Therapeutics	-$512.54M	-$2.84	N/A	N/A	N/A	N/A	-55.27%	-44.24%	11/5/2026 (Estimated)
IBRX ImmunityBio	-$351.40M	-$0.97	N/A	N/A	N/A	-598.55%	N/A	-51.65%	11/3/2026 (Estimated)
MDGL Madrigal Pharmaceuticals	-$288.28M	-$12.89	N/A	83.59	N/A	-25.32%	-56.65%	-25.53%	11/3/2026 (Estimated)

Latest DNLI, BEAM, IBRX, and MDGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	DNLI Denali Therapeutics	-$0.3717	N/A	N/A	N/A	$12.22 million	N/A
11/3/2026	Q3 2026	BEAM Beam Therapeutics	-$1.15	N/A	N/A	N/A	$8.75 million	N/A
11/3/2026	Q3 2026	IBRX ImmunityBio	-$0.07	N/A	N/A	N/A	$59.23 million	N/A
11/3/2026	Q3 2026	MDGL Madrigal Pharmaceuticals	-$0.8345	N/A	N/A	N/A	$405.27 million	N/A
8/6/2026	Q2 2026	DNLI Denali Therapeutics	-$0.5131	-$0.68	-$0.1670	-$0.68	$2.15 million	$3.60 million
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million
8/4/2026	Q2 2026	IBRX ImmunityBio	-$0.08	-$0.22	-$0.14	-$0.22	$49.70 million	$51.24 million
7/30/2026	Q2 2026	MDGL Madrigal Pharmaceuticals	-$2.68	-$1.99	+$0.69	-$1.99	$352.13 million	$364.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	0.09	14.57	14.57
DNLI Denali Therapeutics	0.01	8.37	8.32
IBRX ImmunityBio	N/A	5.72	5.70
MDGL Madrigal Pharmaceuticals	0.65	3.20	2.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
DNLI Denali Therapeutics	92.92%
IBRX ImmunityBio	8.58%
MDGL Madrigal Pharmaceuticals	98.50%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.80%
DNLI Denali Therapeutics	9.70%
IBRX ImmunityBio	66.10%
MDGL Madrigal Pharmaceuticals	17.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	540	103.29 million	99.36 million	Optionable
DNLI Denali Therapeutics	507	159.85 million	144.34 million	Optionable
IBRX ImmunityBio	691	1.06 billion	359.28 million	Optionable
MDGL Madrigal Pharmaceuticals	915	23.10 million	19.04 million	Optionable

DNLI, BEAM, IBRX, and MDGL Headlines

Recent News About These Companies

UBS raises target to USD 735.00 for Madrigal Pharmaceuticals stock

October 17 at 9:13 PM | ad-hoc-news.deA

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - October 15, 2026

October 16 at 2:48 PM | biospace.comB

UBS lifts target for Madrigal Pharmaceuticals stock to USD 735.00

October 15 at 6:27 PM | ad-hoc-news.deA

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

October 15 at 4:05 PM | globenewswire.com

Madrigal Pharmaceuticals, Inc. $MDGL Shares Newly Acquired by Sivik Global Healthcare LLC

October 13, 2026 | marketbeat.com

Head to Head Analysis: Madrigal Pharmaceuticals (NASDAQ:MDGL) & Aurinia Pharmaceuticals (NASDAQ:AUPH)

October 12, 2026 | americanbankingnews.com

Analysts Are Bullish on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Altimmune (ALT)

October 10, 2026 | theglobeandmail.com

Madrigal Pharmaceuticals (MDGL) Stock Trades At A Discount Following A Very Large 5 Year Run

October 8, 2026 | uk.finance.yahoo.com

Madrigal Pharmaceuticals (MDGL) Genetics Update Keeps Fair Value In Focus

October 8, 2026 | finance.yahoo.com

Is Rezdiffra’s Genetic-Risk Agnostic Data Reframing The Investment Case For Madrigal Pharmaceuticals (MDGL)?

October 7, 2026 | finance.yahoo.com

Madrigal Pharmaceuticals stock gets fresh Rezdiffra data

October 7, 2026 | ad-hoc-news.deA

Madrigal Pharmaceuticals, Inc. Announces Publication In The Journal Of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants

October 6, 2026 | marketscreener.comM

Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants

October 6, 2026 | globenewswire.com

Madrigal Pharmaceuticals stock reports 71 percent revenue growth in Q2

October 4, 2026 | ad-hoc-news.deA

Barclays Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)

October 2, 2026 | theglobeandmail.com

Analysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Madrigal Pharmaceuticals (MDGL)

September 25, 2026 | theglobeandmail.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Moved Up to "Strong-Buy" by The Goldman Sachs Group

September 25, 2026 | marketbeat.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded to Strong-Buy at Citigroup

September 25, 2026 | marketbeat.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

September 25, 2026 | marketbeat.com

Citigroup Initiates Madrigal Pharmaceuticals at Buy With $725 Price Target

September 23, 2026 | marketscreener.comM

Madrigal Pharmaceuticals stock falls 1.80 percent as valuation stays high

September 22, 2026 | ad-hoc-news.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DNLI, BEAM, IBRX, and MDGL Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$23.47 -1.26 (-5.10%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$23.60 +0.13 (+0.56%)

As of 10/16/2026 07:50 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Denali Therapeutics NASDAQ:DNLI

$17.61 -0.73 (-3.98%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$17.92 +0.32 (+1.79%)

As of 10/16/2026 07:30 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

ImmunityBio NASDAQ:IBRX

$9.18 -0.82 (-8.20%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$9.20 +0.02 (+0.17%)

As of 10/16/2026 07:59 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Madrigal Pharmaceuticals NASDAQ:MDGL

$449.74 -10.07 (-2.19%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$449.75 +0.01 (+0.00%)

As of 10/16/2026 07:30 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DNLI, BEAM, IBRX, and MDGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DNLI, BEAM, IBRX, and MDGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DNLI, BEAM, IBRX, and MDGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DNLI, BEAM, IBRX, and MDGL Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Denali Therapeutics NASDAQ:DNLI

ImmunityBio NASDAQ:IBRX

Madrigal Pharmaceuticals NASDAQ:MDGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DNLI, BEAM, IBRX, and MDGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DNLI, BEAM, IBRX, and MDGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DNLI, BEAM, IBRX, and MDGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DNLI, BEAM, IBRX, and MDGL Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Denali Therapeutics NASDAQ:DNLI

ImmunityBio NASDAQ:IBRX

Madrigal Pharmaceuticals NASDAQ:MDGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools